Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$168.57+2.3%$174.73$141.72▼$219.34$4.76B0.75296,211 shs303,757 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+2.35%+4.93%-10.57%+13.60%-0.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRYSKrystal Biotech4.7213 of 5 stars4.51.00.04.72.93.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 3.00Buy$220.0030.51% UpsideCurrent Analyst Ratings BreakdownLatest KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025KRYSKrystal BiotechJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$245.002/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$221.00 ➝ $221.002/20/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$206.00 ➝ $215.002/20/2025KRYSKrystal BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$215.002/20/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$212.00 ➝ $218.002/19/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$221.00 ➝ $221.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M16.77$4.28 per share39.38$32.85 per share5.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$10.93M$2.9956.3816.72N/A30.69%11.41%10.40%5/5/2025 (Estimated)Latest KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025KRYSKrystal Biotech$1.35N/AN/AN/A$98.66 millionN/A2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A7.287.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableKRYS HeadlinesRecent News About These CompaniesBank of America Securities Sticks to Their Buy Rating for Krystal Biotech (KRYS)April 18 at 1:58 AM | markets.businessinsider.comFate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT TagApril 15 at 3:29 PM | msn.comKennedy Capital Management LLC Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)April 15 at 6:02 AM | marketbeat.comAbeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term UpsideApril 14, 2025 | seekingalpha.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Evolutionary Tree Capital Management LLCApril 14, 2025 | marketbeat.comCenterBook Partners LP Buys Shares of 4,283 Krystal Biotech, Inc. (NASDAQ:KRYS)April 14, 2025 | marketbeat.comBrokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $220.00April 14, 2025 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Buy" from AnalystsApril 13, 2025 | marketbeat.comExodusPoint Capital Management LP Buys Shares of 9,761 Krystal Biotech, Inc. (NASDAQ:KRYS)April 12, 2025 | marketbeat.comJPMorgan Chase & Co. Buys 23,934 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)April 12, 2025 | marketbeat.comFmr LLC Increases Position in Krystal Biotech, Inc. (NASDAQ:KRYS)April 11, 2025 | marketbeat.comOLD Mission Capital LLC Buys Shares of 1,868 Krystal Biotech, Inc. (NASDAQ:KRYS)April 9, 2025 | marketbeat.comKrystal Biotech, Inc.: Jeune Aesthetics Appoints Marc Forth as Chief Executive OfficerApril 8, 2025 | finanznachrichten.deKrystal Biotech’s Jeune Aesthetics names Marc Forth as CEOApril 8, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for Krystal Biotech Q1 EarningsApril 8, 2025 | americanbankingnews.comKrystal Biotech Q1 EPS Forecast Reduced by William BlairApril 8, 2025 | marketbeat.comJeune Aesthetics Appoints Marc Forth as Chief Executive OfficerApril 7, 2025 | globenewswire.com5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025April 7, 2025 | zacks.comRhenman & Partners Asset Management AB Buys 6,750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)April 7, 2025 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Headlands Technologies LLCApril 7, 2025 | marketbeat.comFranklin Resources Inc. Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS Company DescriptionsKrystal Biotech NASDAQ:KRYS$168.57 +3.87 (+2.35%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$168.46 -0.10 (-0.06%) As of 04/17/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
